share_log

Baird Maintains Outperform on Instil Bio, Lowers Price Target to $31

Baird Maintains Outperform on Instil Bio, Lowers Price Target to $31

貝爾德維持Instil Bio的跑贏大盤,將目標股價下調至31美元
Benzinga Real-time News ·  2022/09/06 09:08

Baird analyst Jack Allen maintains Instil Bio (NASDAQ:TIL) with a Outperform and lowers the price target from $34 to $31.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論